Methotrexate for Cardiovascular Risk Reduction: The Right Choice?

Reiner, Željko; Sirtori, Cesare R.; Banach, Maciej; Ruscica, Massimiliano; Sahebkar, Amirhossein

doi:10.1177/0003319719855165

Cited by 11 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a well-documented role of inflammation in MACE pathogenesis, and inflammation has been a major treatment target. Several anti-inflammatory drugs are being clinically used, not only to treat inflammation, but also to reduce risk of CVD [ 16 , 97 ], although findings have been mixed depending on specific characteristics of the population of interest [ 98 ]. For example, methotrexate (MTX) is a disease-modifying antirheumatic drug used for treatment of chronic inflammatory disorders [ 16 ] and a first line-therapy drug for patients with rheumatoid arthritis (RA) [ 16 , 97 ].…”

Section: Anti-inflammatory Pharmacological Interventions Against Mace...mentioning

confidence: 99%

Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research

Bikomeye

Beyer

Kwarteng

et al. 2022

IJERPH

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a leading cause of global morbidity and mortality. Cancer survivors have significantly elevated risk of poor cardiovascular (CV) health outcomes due to close co-morbid linkages and shared risk factors between CVD and cancer, as well as adverse effects of cancer treatment-related cardiotoxicity. CVD and cancer-related outcomes are exacerbated by increased risk of inflammation. Results from different pharmacological interventions aimed at reducing inflammation and risk of major adverse cardiovascular events (MACEs) have been largely mixed to date. Greenspaces have been shown to reduce inflammation and have been associated with CV health benefits, including reduced CVD behavioral risk factors and overall improvement in CV outcomes. Greenspace may, thus, serve to alleviate the CVD burden among cancer survivors. To understand pathways through which greenspace can prevent or reduce adverse CV outcomes among cancer survivors, we review the state of knowledge on associations among inflammation, CVD, cancer, and existing pharmacological interventions. We then discuss greenspace benefits for CV health from ecological to multilevel studies and a few existing experimental studies. Furthermore, we review the relationship between greenspace and inflammation, and we highlight forest bathing in Asian-based studies while presenting existing research gaps in the US literature. Then, we use the socioecological model of health to present an expanded conceptual framework to help fill this US literature gap. Lastly, we present a way forward, including implications for translational science and a brief discussion on necessities for virtual nature and/or exposure to nature images due to the increasing human–nature disconnect; we also offer guidance for greenspace research in cardio-oncology to improve CV health outcomes among cancer survivors.

show abstract

Section: Anti-inflammatory Pharmacological Interventions Against Mace...mentioning

confidence: 99%

Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research

Bikomeye

Beyer

Kwarteng

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…It has been shown that approximately 42 million people are affected by CVDs (Roth et al, 2017). These estimates provide an urge for the development of novel strategies in the management and treatment of CVDs (Reiner, Sirtori, Banach, Ruscica, & Sahebkar, 2019 generation of CVDs (Tong et al, 2019). Studies have manifested the impact of Wnt signaling pathway on the cardiometabolic health by modulation of lipoprotein receptor-related protein (Cheng et al, 2015).…”

Section: Protection Against Ischemic/reperfusion Injurymentioning

confidence: 99%

“…It has been shown that approximately 42 million people are affected by CVDs (Roth et al, ). These estimates provide an urge for the development of novel strategies in the management and treatment of CVDs (Reiner, Sirtori, Banach, Ruscica, & Sahebkar, ). Investigation of molecular signaling pathways has demonstrated the potential role of the Wnt signaling pathway in the generation of CVDs (Tong et al, ).…”

Section: Therapeutic and Biological Activities Of Res Mediated By Wnt Signaling Pathwaymentioning

confidence: 99%

Resveratrol targeting the Wnt signaling pathway: A focus on therapeutic activities

Ashrafizadeh

Ahmadi

Farkhondeh

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Wingless-type MMTV integration site (Wnt) signaling pathway is considered as an important pathway regulating a variety of biological processes such as tissue formation and homeostasis, cell proliferation, cell migration, cell differentiation, and embryogenesis. Impairment in the Wnt signaling pathway is associated with pathological conditions, particularly cancer. So, modulation of this pathway can be considered as a promising strategy and several drugs have been developed in line with this strategy. Resveratrol (Res) is a naturally occurring nutraceutical compound exclusively found in different fruits and nuts such as grape, peanut, and pistachio. This compound has favorable biological and therapeutic activities such as antioxidant, anti-inflammatory, antitumor, hepatoprotective, cardioprotective, and antidiabetic. At the present review, we demonstrate how Res modulates Wnt signaling pathway to exert its pharmacological effects.

show abstract

“…Theoretically, targeting proinflammatory cytokines could be a valuable therapeutic approach in the prevention and treatment of CAD. Hence this hypothesis was tested in clinical trials using a range of anti‐inflammatory agents, but the results were conflicting 4–6 …”

Section: Introductionmentioning

confidence: 99%

“…Hence this hypothesis was tested in clinical trials using a range of anti-inflammatory agents, but the results were conflicting. [4][5][6] Colchicine is an anti-inflammatory drug, originally extracted from the Colchicum autumnale, a plant used by the ancient Greeks and Egyptians. In contrast to other anti-inflammatory drugs, colchicine has broad cellular effects through inhibition of tubulin polymerization and alteration of leucocyte responsiveness.…”

mentioning

confidence: 99%

Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials

Bytyçi

Bajraktari

Penson

et al. 2021

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing cardiovascular (CV) events in patients with coronary artery disease (CAD) but produced conflicting results. The aim of this meta-analysis was to evaluate the efficacy and safety of colchicine in patients with CAD.Methods: We systematically searched selected electronic databases from inception until 10 December 2020. Primary clinical endpoints were: major adverse cardiac events; all-cause mortality; CV mortality; recurrent myocardial infarction; stroke; hospitalization; and adverse medication effects. Secondary endpoints were shortterm effect of colchicine on inflammatory markers.Results: Twelve randomized controlled trials with a total of 13 073 patients with CAD (colchicine n = 6351 and placebo n = 6722) were included in the meta-analysis.At mean follow-up of 22.5 months, the colchicine group had lower risk of major adverse cardiac events (6.20 vs. 8.87%; P < .001), recurrent myocardial infarction (3.41 vs. 4.41%; P = .005), stroke (0.40 vs. 0.90%; P = .002) and hospitalization due to CV events (0.90 vs. 2.87%; P = .02) compared to the control group. The 2 patient groups had similar risk for all-cause mortality (2.08 vs. 1.88%; P = .82) and CV mortality (0.71 vs. 1.01%; P = .38). Colchicine significantly reduced high-sensitivity C-reactive protein (À4.25, P = .001) compared to controls but did not significantly affect interleukin (IL)-β1 and IL-18 levels. Conclusion:Colchicine reduced CV events and inflammatory markers, highsensitivity C-reactive protein and IL-6, in patients with coronary disease compared to controls. Its impact on cardiovascular and all-cause mortality requires further investigation.

show abstract

Methotrexate for Cardiovascular Risk Reduction: The Right Choice?

Cited by 11 publications

References 28 publications

Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research

Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research

Resveratrol targeting the Wnt signaling pathway: A focus on therapeutic activities

Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials

Contact Info

Product

Resources

About